Agios Pharmaceuticals Inc... (AGIO)
NASDAQ: AGIO
· Real-Time Price · USD
37.01
0.88 (2.44%)
At close: Sep 05, 2025, 11:59 AM
2.44% (1D)
| Bid | 36.95 |
| Market Cap | 2.15B |
| Revenue (ttm) | 40.88M |
| Net Income (ttm) | 650.08M |
| EPS (ttm) | 11.29 |
| PE Ratio (ttm) | 3.28 |
| Forward PE | -5.6 |
| Analyst | Buy |
| Ask | 37.11 |
| Volume | 585,431 |
| Avg. Volume (20D) | 876,592.9 |
| Open | 36.63 |
| Previous Close | 36.13 |
| Day's Range | 35.94 - 37.91 |
| 52-Week Range | 23.42 - 62.58 |
| Beta | 0.80 |
About AGIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AGIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AGIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Agios Pharmaceuticals Inc. is scheduled to release its earnings on
Oct 30, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
-11.03%
Agios Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
1 month ago
+3.31%
AGIO stock has given up its prior gain. Agios Pharmaceuticals shares were trading higher amid reports of Pyrukynd patient deaths.
17 hours ago · seekingalpha.com
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be MitigatedAgios Pharmaceuticals, Inc. faces a three-month FDA review delay for mitapivat in thalassemia due to safety concerns, but no new efficacy or safety data was requested. Despite the setback, I remain co...
1 month ago · seekingalpha.com
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call TranscriptAgios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Ch...
